Long QT syndrome induced by elevated dose of Fluoxetine Cloridrate: case report
Main Article Content
Abstract
Introduction: Long QT syndrome is a clinical condition that affects cardiac repolarization with an increased risk for the development of severe ventricular arrhythmias. The acquired form can be induced by drugs, such as selective serotonin reuptake inhibitors. Case report: E.A.C.G., female, 83 years-old, previously diagnosed with major depressive disorder in use of Fluoxetine the 80mg/day, was admitted in the emergency department after a syncopal event. An important widening of the QT interval was noted on the occasion, with a corrected value of 580ms. A 24-hour Holter monitoring showed increased ectopic ventricular activity (18% of beats), prolonged QT interval (up to 630 ms), and high-complexity ectopic ventricular beats. Non-sustained ventricular tachycardia was also observed (1030 episodes). The prolonged QT interval was associated to an elevated dose of Fluoxetine. Discussion: We believe that the coexistence between a high dose of Fluoxetine and other risk factor such as female sex and increased age contributed to the development of the case presentation. Conclusion: The rising prevalence of depression in the geriatric population and the indiscriminate use of antidepressive agents such as selective serotonin reuptake inhibitors may contribute to an increase in potentially severe cardiovascular complications.
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
References
Zeppenfeld K, Tfelt-Hansen J, de Riva M, Winkel BG, Behr ER, Blom NA, et al. 2022 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death. Eur Heart J. 2022;43:3997–4126.
Ehmke CJ, Nemeroff CB. Paroxetine. In: The American Psychiatric Publishing Textbook of Psychopharmacology. 4th ed. Washington, DC: American Psychiatric Publishing, Inc; 2009. p. 321.
Wehrens XHT, Vos MA, Doevendans PA, Wellens HJJ. Novel insights in the congenital long QT syndrome. Ann Intern Med. 2002;137:981–992.
Colivicci F, Ammirati F, Melina D, Guido V, Imperoli G, Santini M, et al. Development and prospective validation of a risk stratification system for patients with syncope in the emergency department: the OESIL risk score. Eur Heart J. 2003;24(9):811-9.
Brignole M, Disertoni M, Menozzi C, Raviele A, Alboni P, Pitzalis MV, et al; Evaluation of Guidelines in Syncope Study group. Management of syncope referred urgently to general hospitals with and without syncope units. Europace. 2003;5(3):293-8.
Johannesen L, Vicente J, Mason JW, Erato C, Sanabria C, Waite-Labott K, et al. Late sodium current block for drug-induced long QT syndrome: Results from a prospective clinical trial. Clin Pharmacol Ther. 2016;99:214–223.
Tooley J, Ouyang D, Hadley D, et al. Comparison of QT Interval Measurement Methods and Correction Formulas in Atrial Fibrillation. Am J Cardiol. 2019;123(11):1822-1827.
Santos ECL, et al. Manual de Emergências Cardiovasculares: cardiopapers. 2021;1(1):59-61.
Soeiro AM, et al. Manual da Residência em Cardiologia: USP. 2021:194-199; 497-498; 835-841.
Steinberg C. Diagnosis and clinical management of long-QT syndrome. Curr Opin Cardiol. 2018;33(1):31–41.
Shah SR, Park K, Alweis R. Long QT Syndrome: A Comprehensive Review of the Literature and Current Evidence. Curr Probl Cardiol. 2019;44(3):92–106.
Schwartz PJ, Crotti L, Insolia R. Long-QT Syndrome: From Genetics to Management. Circ Arrhythm Electrophysiol. 2012;5(4):868–877.
Carter C, Shah M. Long QT syndrome: A therapeutic challenge. Ann Pediatr Card. 2008;1(1):18–26.